AZTA
Hot AirAzenta, Inc. · Healthcare · United States · $1.6B cap · $58.2M/day traded
$48.90 +20.8% · close 11 Nov · scored 11 Nov
Hot Air: Strong momentum and nothing else: weak business, rich price.
As of 11 Nov 2026, the MoatMap Score for Azenta, Inc. (AZTA) is 45/100, ranked against 25,000+ stocks in 38 markets (Quality 45, Value 29, Momentum 65, each scored against its sector).
Does the score work? Each tenth of the ranking, tracked monthly. See the record →
ABOUT AZENTA, INC.
Read
Azenta, Inc. provides life sciences solutions, including automated sample management systems, consumables, and genomics services to pharmaceutical, biotech, and academic researchers. A leader in its field, its integrated solutions, proprietary automation, and global infrastructure improve research efficiency and reliability, creating a competitive advantage. Azenta is a pure-play life sciences technology company, well-positioned for growth in genomics and sample preservation.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 555.5M | 551.5M | 573.4M | 593.8M | 2.2% | 613.8M | 614.8M | 639.3M | 3.8% |
| EPS | 28.48 | -0.22 | -3.60 | -1.30 | — | -2.47 | — | — | — |
| Shares | 75.0M | 57.8M | 45.6M | 45.9M | -38.9% | 43.8M | — | — | — |
| Debt | 49.2M | 60.4M | 56.7M | 51.2M | 1.3% | 54.0M | — | — | — |
| Equity | 3.4B | 2.5B | 1.8B | 1.7B | -19.9% | — | — | — | — |
| Op CF | -466.0M | 5.8M | 49.7M | 72.2M | 251.7% | 38.0M | — | — | — |
| Inv CF | 1.5B | 431.4M | 224.7M | -90.5M | — | — | — | — | — |
| Fin CF | -62.8M | -840.5M | -659.2M | -9.6M | — | — | — | — | — |
No clear trend: not near its 52-week low, and not in a steady uptrend.
Swung more than 78% of stocks we rank over the past year (volatility 65% a year).
How this is worked out
The MoatMap Score weighs the business, its price and its trend. The price check reads only the chart: the price side of the Momentum score, in words.
The rules: Still falling is a new 52-week low in the last two weeks, at least 25% below the high. Finding a floor is no new low since. Turning up is 20 or more trading days without a new low, at least 10% off it, and back above a rising 50-day average. In an uptrend is above the 200-day average and within 15% of the high.
In 2,112 US drawdowns since 2001, buying while the price was still falling was followed by a further 20% drop 42% of the time. Waiting for a turn (the Turning up rule above) cut that to 33%, at about 7% higher prices and with no better returns. Part of that cut is simply not buying: 13% of falls never turned, and waiting kept those out. Among turns that were bought, 38% still fell another 20%, and 33% of turns were followed by a new low within six months. The benefit was largest in crashes such as 2008 and 2020.
What it measures: how much the price moved day to day over the past year, scaled to a yearly figure (annualised volatility) and ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.
What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.
Calm is not safe: a calm stock can still slide steadily.
Rules fixed before any data was fetched. Describes the chart, not a recommendation.
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of AZTA are excluded.
| Ticker | Company | Mkt Cap | Score |
|---|---|---|---|
| AZTA | Azenta, Inc.(you) | $1.6B | 45 |
| LMAT | LeMaitre Vascular, Inc. | $1.9B | 50 |
| XRAY | DENTSPLY SIRONA Inc. | $1.9B | 51 |
| KMTS | Kestra Medical Technologies, Ltd. | $1.7B | 29 |
| STAA | STAAR Surgical Company | $1.1B | 31 |
| WRBY | Warby Parker Inc. | $3.2B | 54 |
| ATRC | AtriCure, Inc. | $3.0B | 61 |
| ANGO | AngioDynamics, Inc. | $520M | 34 |
| PLSE | Pulse Biosciences, Inc. | $3.8B | 28 |
| MMED | MiniMed Group, Inc. | $5.2B | 59 |
Peer medians: ROE -31.0% · P/E 25.9x · Gross margin 63.3%
Company Deep Dive
A 10,000-word report: the business and its segments, what management promised on earnings calls and whether it delivered, the competition, and how things could turn out.